Gene therapy (Lentiviral vector) · Acts on B-lymphocyte antigen CD19 (CD19) and B-lymphocyte antigen CD20 (MS4A1)
CD19/CD20 Dual-Target in vivo CAR-T Lentiviral is a lentiviral product intended to make CAR-T cells inside the body, directed at the CD19 and CD20 antigens on B cells. It is being studied in relapsed or refractory B-cell malignancies, with bridging therapy given before infusion if needed.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07763938 | Phase 1 | Relapsed/Refractory B-cell Malignancies | Not yet recruiting | LEGN |
| NCT07002112 | Phase 1 | Relapsed/Refractory B-cell Malignancies | Recruiting | LEGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed/Refractory B-cell Malignancies
Updated Oct 18, 2026.